Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
Portfolio Pulse from Vandana Singh
Biogen and Eisai's Alzheimer's drug Leqembi received a negative opinion from the European Medicines Agency's advisory panel due to serious side effects. This decision impacts Biogen's stock, which fell by 6.11%. Eisai plans to seek re-examination of the decision.
July 26, 2024 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen's Alzheimer's drug Leqembi received a negative opinion from the European Medicines Agency's advisory panel due to serious side effects, leading to a 6.11% drop in its stock price.
The negative opinion from the European Medicines Agency's advisory panel is a significant regulatory setback for Biogen's Alzheimer's drug Leqembi. This has led to a notable drop in Biogen's stock price, reflecting investor concerns about the drug's future in the European market.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Eli Lilly's Alzheimer's treatment donanemab received a favorable verdict from the FDA's advisory committee, contrasting with the negative opinion on Biogen's Leqembi.
The favorable verdict from the FDA's advisory committee on Eli Lilly's Alzheimer's treatment donanemab highlights a positive regulatory environment for the company, especially in contrast to the setback faced by Biogen's Leqembi in Europe. This could boost investor confidence in Eli Lilly's Alzheimer's drug pipeline.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50